

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/8/2011; page 1 TMP 045

Suggested Formula	Tranexamic Acid 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 004 310v2
----------------------	-----------------------------------------------------------------------------	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Tranexamic Acid, BP	25.000	g				
Medisca CapsuBlend™-S	TBD					
Sodium Chloride, USP	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information		
Hygroscopic (protect from mois	ture whenever possible):	$CapsuBlend^{TM}$ - S
Suggested Preparatory Guidelines		
Non-Sterile Preparation	on Sterile Preparation	Or
		considerations during preparation, it is suggested to the required quantities of ingredients.
	Protective apparel, such as a lab c should always be worn.	oat, disposable gloves, eyewear and face-masks
		very small quantities of ingredients. All calculations be verified before dispensing the final product.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/8/2011; page 2

Suggested Formula

Tranexamic Acid 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)

FIN

F 004 310v2

SUGGESTED PREPARATION (for 100 Size #0 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Tranexamic Acid, BP	25.000	g			
Medisca CapsuBlend™-S §	TBD				
Sodium Chloride, USP	As required		⊗		

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

Preparatory Instruction

1. CapsuBlendTM-S requirements for 100 x size #0 capsules

A. Calculate the amount of CapsuBlend™-S required for the batch. Refer to attached appendix for details.

2. **Powder preparation:**

- A. By geometric addition, combine and mix the following ingredients together:
 - -Tranexamic Acid
 - -CapsuBlendTM-S (Quantity determined in appendix (**I**))

3. **Product transfer:**

Fill each of 100 Size #0 capsules with the powder blend (Step 2A). Close each capsule tightly.

Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.

4. Validation technique (average capsule weight):

The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (G) + 0.250 g together.

5. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/8/2011; page 3

Suggested Formula	Tranexamic Acid 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 004 310v2	
----------------------	-----------------------------------------------------------------------------	-----	-------------	--

SUGGESTED PRESENTATION

Estima Beyond-Use D		6 months, as per USP.	Packa Requirem		Tightly closed vials.	
	1	Use as directed. Do not exceed dose.	l prescribed	4	Keep in a dry place.	
Auxiliary	2			5	Keep at room temperature (20°C – 23°C).	
Labels	3	3 Cap tightly after use.		6	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary				nsing container as deemed necessary.	
					is.	

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition.</i> American Pharmaceutical Association; 2008: 127.
2.	Tranexamic Acid Injection BP. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2009: 2345.
3.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 6 th Edition. American Pharmaceutical Association; 2009: 637.
4.	Tranexamic Acid. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1080.
5.	Tranexamic Acid (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #9569.
6.	Tranexamic Acid Systemic. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition.</i> Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2876.
7.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/8/2011; page 1

Appendix	Calculating the quantity of excipient required for the batch	
	•	

		Procedure		
1.	Capsule filling: a. For each ingredient powder below, de CAPSULES. Do not forget to divide Plug each amount into Step 2, column	the total weight by 5 to ob	· .	2 2
2.	Volume Percent Occupied:		⊗	
	<u>Ingredients</u>	Column A Quantity Required per capsule	Column B Average capsule fill weight	Column C A/B x 100 equals percent filled
	a. Tranexamic Acid	0.250 g	g	%
	b. CapsuBlend™-S	6,10	g	
	c. Total (add column C together)			% (D)
3.	Calculate the quantity of CapsuBlend TM	-S required for the batch	<u>:</u>	
	a. Percent of CapsuBlend TM -S required =	100% – (D)		% (E)
	b. Average capsule fill weight of CapsuB	Blend™-S (from column B,	Step 2b):	g (F)
	c. Quantity of CapsuBlend™-S required J	per capsule = $[(E) \div 100 \times$	(F)]	g (G)
	d. Total quantity of CapsuBlend™-S requ	nired for the batch = 100 ca	apsules × (G)	g (H)
	e. Total quantity of CapsuBlend TM -S <i>plus</i>	processing error = $(H) \times 1$	1.05-1.09	g (I)

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.